Restraints & Challenges:
Global Array Market (Life Science and Biotechnology Instruments) – Impact of Coronavirus (COVID-19) Pandemic
Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.
The COVID-19 pandemic had a positive impact on the global array market (Life Science and Biotechnology Instruments), owing to increased research and development activities using array in the treatment of patients suffering from COVID-19. For instance, in August 2020, according to the report published by Aurora Biomed Inc., a provider of lab automation solutions for life science, environmental science, drug discovery and safety and chemical analysis research, microarray, including cell microarray, protein microarrays, and DNA and RNA microarray, are all considered powerful tools in the ongoing research related to COVID-19. These microarrays can analyze hundreds or even thousands of samples in a single run, making them much faster than traditional virus detection methods. These techniques allow researchers to rapidly screen for the presence of viral proteins in samples, providing valuable information about the virus and its behavior.
Furthermore, in January 2022, according to the published article titled "Systematic Investigation of SARS-CoV-2 Receptor Protein Distribution along Viral Entry Routes in Humans", tissue microarrays incorporating a total of 879 tissue cores from conjunctival (n = 84), sinonasal (n = 95), and lung (bronchiolar/alveolar; n = 96) specimens were investigated for protein expression by immunohistochemistry. The study confirms and extends previous findings and contributes to a better understanding of potential SARS-CoV-2 infection sites along the human respiratory tract. Such studies indicate significant demand for tissue microarray products amid the pandemic.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients